Wohl D, et al. Patient-reported outcomes among HIV-1-infected adults randomized to B/F/TAF versus DTG/ABC/3TC in two Phase 3 controlled clinical trials over 48 weeks. AIDS 2018.
PREVAIL IV: vaker ebolavirus-RNA-negatief na behandeling remdesivir
jul 2021 | Virale infecties